Drug Type Small molecule drug |
Synonyms BAY 2402234 |
Target |
Mechanism DHODH inhibitors(Dihydroorotate dehydrogenase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H18ClF5N4O4 |
InChIKeyKNVJMHHAXCPZHF-JTQLQIEISA-N |
CAS Registry2225819-06-5 |
Start Date01 Dec 2021 |
Sponsor / Collaborator |
Start Date29 Mar 2018 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioma | Phase 1 | - | 01 Dec 2021 | |
Myeloid Tumor | Phase 1 | US | 29 Mar 2018 | |
Myeloid Tumor | Phase 1 | FR | 29 Mar 2018 | |
Acute Myeloid Leukemia | Phase 1 | FR | 10 Mar 2018 | |
Chronic Myelomonocytic Leukemia | Phase 1 | US | 09 Mar 2018 | |
Myelodysplastic Syndromes | Phase 1 | US | 06 Mar 2018 | |
Small Cell Lung Cancer | Preclinical | DE | 09 Apr 2021 | |
Lymphoma | Preclinical | DE | 25 Jan 2019 | |
Colorectal Cancer | Preclinical | DE | 18 Dec 2018 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |